Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 |
filingDate |
2000-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2003-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2003511077-A |
titleOfInvention |
Methods and compositions for cell targeting |
abstract |
(57) [Summary] Oligomeric ligands such as cysteine knot growth factor can be displayed on the surface of virus particles as recombinant fusion proteins. Recombinant fusion proteins can be screened to obtain agents that inhibit the binding of oligomeric ligands to their receptors, and target transposable labels containing therapeutic gene products to cells with receptors specific for oligomeric ligands Can be used to |
priorityDate |
1999-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |